Table 1 Baseline demographics and assessments
| Â | Diclofenac sodium 1% gel | Vehicle | Combined |
|---|---|---|---|
| Â | n = 400 | n = 383 | n = 783 |
Percentage of female patients | 79.3 | 81.2 | 80.2 |
Percentage of white patients | 93.0 | 94.3 | 93.6 |
Age, years | Â | Â | Â |
   Mean (SD) | 63.8 (10.0) | 64.1 (9.7) | 63.9 (9.8) |
   Range | 40-92 | 40-87 | 40-92 |
Body mass index, kg/m2 | Â | Â | Â |
   Mean (SD) | 27.5 (5.4) | 27.5 (5.6) | 27.5 (5.5) |
   Range | 17.4-55.0 | 14.3-49.8 | 14.3-55.0 |
VAS pain intensity | Â | Â | Â |
   Mean (SD) | 71.1 (15.3) | 71.1 (14.8) | 71.1 (15.1) |
   Range | 26-100 | 4-100 | 4-100 |
AUSCAN pain | Â | Â | Â |
   Mean (SD) | 63.9 (17.5) | 63.4 (17.7) | 63.7 (17.6) |
   Range | 11.6-98.4 | 10.4-99.0 | 10.4-99.0 |
AUSCAN stiffness | Â | Â | Â |
   Mean (SD) | 60.4 (24.7) | 59.7 (25.7) | 60.0 (25.2) |
   Range | 1-98 | 0-100 | 0-100 |
AUSCAN function | Â | Â | Â |
   Mean (SD) | 65.9 (18.1) | 64.6 (18.8) | 65.3 (18.4) |
   Range | 8.9-98.7 | 8.3-99.2 | 8.3-99.2 |
Global rating of disease | Â | Â | Â |
   Mean (SD) | 56.9 (18.1) | 56.7 (18.7) | 56.8 (18.4) |
   Range | 5-97 | 9-98 | 5-98 |